Yield10 Bioscience to Delist From Nasdaq; Shares Drop-April 2024-www.financetom.com

Yield10 Bioscience to Delist From Nasdaq; Shares Drop

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Yield10 Bioscience to Delist From Nasdaq; Shares Drop

May 15, 2024 8:38 AM

11:14 AM EDT, 05/15/2024 (MT Newswires) -- Yield10 Bioscience ( YTEN ) said Wednesday it received a final delisting notice from Nasdaq after failing to regain compliance with the exchange's listing rule that requires listed firms to maintain stockholder's equity of at least $2.5 million.

The company said trading of its shares on the exchange will be suspended at market open Thursday.

Yield10 said its shares will trade on the over-the-counter market, and it plans to apply for trading on the OTC-QB market.

The company shares were down about 43% in recent trading.

Price: 2.98, Change: -2.28, Percent Change: -43.35

Previous page： Asset Entities Files $100 Million Shelf Offering Next page： Johnson & Johnson Narrows Full-Year Outlook as First-Quarter Sales Miss Street Views

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Asset Entities Files $100 Million Shelf Offering

Apr 16, 2024

08:45 AM EDT, 04/16/2024 (MT Newswires) -- Asset Entities ( ASST ) said Tuesday that it has filed a shelf registration statement for the potential sale of up to $100 million of securities from time to time. The company said the filing covers shares of its Class B common stock, preferred stock, debt securities, warrants, subscription rights and units. Asset...

Johnson & Johnson Narrows Full-Year Outlook as First-Quarter Sales Miss Street Views

Apr 16, 2024

08:52 AM EDT, 04/16/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) tightened its full-year outlook on Tuesday after the healthcare products conglomerate reported first-quarter sales slightly below market expectations. Adjusted earnings are now set to come in between $10.57 and $10.72 a share for 2024, compared with the company's previous projections of $10.55 to $10.75. Sales excluding the...

Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers

Apr 16, 2024

08:50 AM EDT, 04/16/2024 (MT Newswires) -- Compass Therapeutics ( CMPX ) said Tuesday it dosed its first patient in its phase 1 trial of CTX-8371, a potential cancer treatment. CTX-8371 is a bispecific checkpoint inhibitor. The study includes five ascending doses of CTX-8371 for patients with melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin Lymphoma,...

What's Going On With PNC Financial Shares Today?

Apr 16, 2024

PNC Financial Services Group Inc ( PNC ) shares are trading lower after it reported first-quarter FY24 results. The bank reported a revenue decline of 8% Y/Y to $5.15 billion, missing the consensus of $5.19 billion. Revenue declined Y/Y due to lower net interest income and noninterest income. Net interest income fell 9% Y/Y to $3.26 billion, with a net interest margin...